A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients

Table 2 Rates of NR*, ETR^† and SVR^‡ in patients infected by different HCV genotypes to interferon plus ribavirin therapy (N = 400).

HCV GENOTYPE	TREATED PATIENTS	NR*	ETR^†	SVR^‡
1 (a, b, c)	70	42 (60%)	28 (40%)	17 (24.3%)
2 (a, b)	33	5 (15.2%)	28 (84.8%)	23 (69.7%)
3 (a, b, c, d)	260	65 (25%)	195 (75%)	149 (57.3%)
Others (4, 5a, 6a)	6	2 (33.3)	4 (66.7%)	3 (50%)
Mixed^ψ	31	18 (58.1%)	13 (41.9%)	10 (32.3%)
Total	400	132 (33%)	268 (67%)	202 (50.5%)

*NR, Non-responders, defined as detectable HCV RNA at the end of anti-viral treatment.
^†ETR, End of treatment response, defined as undetectable HCV RNA at the end of treatment.
^‡SVR-Sustained virologic response, defined as undetectable HCV RNA 24 weeks after end of anti-viral treatment.
^ψOf the 31 patients with mixed genotypes, 13 were with genotypes 3a+3b; 4 with 2a+3b; 3 each with 2a+3a & 1a+1b, 2 each with 1a+3a & 3a+4; 1 each with 1a+3c, 1b+2a, 1c+3b & 1c+3c.

ISSN: 1471-230X